• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    O'Malley Brendan M. bought $27,864 worth of shares (8,600 units at $3.24), increasing direct ownership by 5% to 188,718 units (SEC Form 4)

    4/26/24 8:30:36 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABEO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    O'Malley Brendan M.

    (Last) (First) (Middle)
    6555 CARNEGIE AVE, 4TH FLOOR

    (Street)
    CLEVELAND, OH 44103

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ABEONA THERAPEUTICS INC. [ ABEO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    SVP, General Counsel
    3. Date of Earliest Transaction (Month/Day/Year)
    04/25/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common stock 04/25/2024 P 8,600 A $3.24 188,718 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Brendan O'Malley 04/26/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ABEO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABEO

    DatePrice TargetRatingAnalyst
    3/5/2025$16.00Outperform
    Oppenheimer
    7/3/2024$15.00Buy
    H.C. Wainwright
    5/30/2024$21.00Buy
    Stifel
    11/30/2021$5.00 → $1.00Outperform → Market Perform
    SVB Leerink
    11/29/2021$5.00 → $4.00Buy
    HC Wainwright & Co.
    7/19/2021$8.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ABEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Alvino Mark sold $45,440 worth of shares (8,000 units at $5.68), decreasing direct ownership by 8% to 92,435 units (SEC Form 4)

      4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

      5/16/25 5:23:52 PM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Seshadri Vishwas sold $119,500 worth of shares (25,000 units at $4.78), decreasing direct ownership by 2% to 1,355,322 units (SEC Form 4)

      4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

      3/31/25 7:17:50 PM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Vazzano Joseph Walter covered exercise/tax liability with 685 shares, decreasing direct ownership by 0.13% to 509,041 units (SEC Form 4)

      4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

      3/17/25 4:30:19 PM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABEO
    SEC Filings

    See more
    • SEC Form 144 filed by Abeona Therapeutics Inc.

      144 - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

      5/16/25 4:07:49 PM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Abeona Therapeutics Inc.

      10-Q - ABEONA THERAPEUTICS INC. (0000318306) (Filer)

      5/15/25 7:35:46 AM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abeona Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)

      5/15/25 7:30:12 AM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Alland Leila bought $51,799 worth of shares (11,000 units at $4.71), increasing direct ownership by 15% to 82,857 units (SEC Form 4)

      4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

      5/20/24 8:30:14 AM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seshadri Vishwas bought $32,000 worth of shares (10,000 units at $3.20), increasing direct ownership by 2% to 538,260 units (SEC Form 4)

      4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

      4/29/24 8:30:16 AM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Charles Faith L. bought $24,764 worth of shares (7,550 units at $3.28), increasing direct ownership by 11% to 78,323 units (SEC Form 4)

      4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

      4/29/24 8:30:14 AM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABEO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

      - Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagenezamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adultand pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) - - U.S. launch of ZEVASKYN underway with activation of first qualified treatment center (QTC) - - Entered into sales agreement for priority review voucher (PRV) for $155 million - CLEVELAND, May 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results and business highlights for the first quarter of 2025 and shared recent operational progress. "ZEVASKYN's appr

      5/15/25 7:30:00 AM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

      - ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann & Robert H. Lurie Children's Hospital of Chicago, a top-ranked hospital, is ready to evaluate patients for ZEVASKYN treatment - - Abeona Assist™ comprehensive patient services program in place to offer personalized support for eligible patients and their families throughout ZEVASKYN treatment journey - CLEVELAND and CHICAGO, May 14, 2025 (GLOBE NEWSWIRE) -- Correction for Trademark symbol in headline - Abeona Therapeutics Inc. (NASDAQ:ABEO) and Ann & Robert H. Lurie Children's Hospital of Chicago today announced that L

      5/14/25 8:07:06 AM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

      - ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. - - Ann & Robert H. Lurie Children's Hospital of Chicago, a top-ranked hospital, is ready to evaluate patients for ZEVASKYN treatment - - Abeona Assist™ comprehensive patient services program in place to offer personalized support for eligible patients and their families throughout ZEVASKYN treatment journey - CLEVELAND and CHICAGO, May 14, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) and Ann & Robert H. Lurie Children's Hospital of Chicago today announced that Lurie Children's is now activated as the

      5/14/25 7:30:00 AM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Abeona Therapeutics with a new price target

      Oppenheimer initiated coverage of Abeona Therapeutics with a rating of Outperform and set a new price target of $16.00

      3/5/25 7:50:58 AM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Abeona Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Abeona Therapeutics with a rating of Buy and set a new price target of $15.00

      7/3/24 7:23:46 AM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Abeona Therapeutics with a new price target

      Stifel initiated coverage of Abeona Therapeutics with a rating of Buy and set a new price target of $21.00

      5/30/24 7:24:37 AM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ABEO
    Financials

    Live finance-specific insights

    See more

    $ABEO
    Leadership Updates

    Live Leadership Updates

    See more
    • Amendment: SEC Form SC 13G/A filed by Abeona Therapeutics Inc.

      SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

      11/14/24 7:56:28 PM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Abeona Therapeutics Inc.

      SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

      10/8/24 4:29:58 PM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Abeona Therapeutics Inc. (Amendment)

      SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

      6/3/24 4:30:14 PM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates

      - Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagenezamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adultand pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) - - U.S. launch of ZEVASKYN underway with activation of first qualified treatment center (QTC) - - Entered into sales agreement for priority review voucher (PRV) for $155 million - CLEVELAND, May 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results and business highlights for the first quarter of 2025 and shared recent operational progress. "ZEVASKYN's appr

      5/15/25 7:30:00 AM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

      - ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure - - Approval based on the pivotal Phase 3 VIITAL™ study, showing ZEVASKYN resulted in significant wound healing and pain reduction after a single treatment with a favorable safety profile - - ZEVASKYN to be available through Qualified Treatment Centers beginning in 3Q 2025 - - Abeona Assist™ patient services program offers personalized support for eligible patients and families throughout their treatment journey with ZEVASKYN - - Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA - - Abeona Therapeutics® to host conference call today, Tuesday, April 29, 20

      4/29/25 6:00:00 AM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

      FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025 Launch preparations on track toward goal to treat first patient in 3Q 2025 CLEVELAND, March 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today reported financial results for the full year of 2024, and announced progress in the ongoing review with the U.S. Food and Drug Administration (FDA) regarding prademagene zamikeracel (pz-cel) and plans for the U.S. commercial launch of pz-cel for recessive dystrophic epidermolysis bullosa (RDEB), if approved. The Company will host a conference call and webcast today at

      3/20/25 7:30:00 AM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

      CLEVELAND, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Bernhardt G. Zeiher, MD, FCCP, FACP, and Eric Crombez, MD as new independent members to its Board of Directors. Dr. Zeiher brings more than 20 years of drug development experience where, in various roles, he oversaw the approval of 15 new treatments that addressed unmet needs in serious diseases with few to no treatment options. Dr. Crombez currently serves as Chief Medical Officer of Ultragenyx Pharmaceutical Inc. and brings extensive expertise in the development and execution of clinical development programs for rare genetic disorders. Michael Amoroso, Chairman of Abeon

      8/14/24 7:30:00 AM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer

      CLEVELAND, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Madhav Vasanthavada, Ph.D., M.B.A. to the role of Chief Commercial Officer (CCO) and Head of Business Development (BD), effective immediately. In this capacity, in addition to his current BD responsibilities, Dr. Vasanthavada will oversee all aspects of commercial strategy, planning and operations as Abeona prepares for a potential launch of EB-101, its investigational, genetically engineered autologous cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). Dr. Vasanthavada is a seasoned commercial executive bringing over 20 years of experience with leadershi

      9/12/23 7:30:00 AM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality

      NEW YORK and CLEVELAND, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Jon Voss as Vice President, Head of Quality. Mr. Voss, who has been advising the Company as a consultant, will now serve in a leadership role to further strengthen Abeona's quality system and oversee all quality functions. "Jon is a proven technical leader with a strong track record of successful quality oversight that includes chemistry, manufacturing and control (CMC)-related and clinical functions for gene therapies," said Dr. Vish Seshadri, Ph.D., M.B.A., Head of Research & Clinical Development and CEO-

      10/12/21 7:30:00 AM ET
      $ABEO
      Biotechnology: Pharmaceutical Preparations
      Health Care